Revolution Medicines Inc (RVMD)

Jan 31, 2025

Is Revolution Medicines, Inc. (NASDAQ:RVMD) Trading At A 49% Discount? - Yahoo Finance

Jan 31, 2025

Jan 29, 2025

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times

Jan 29, 2025

Jan 29, 2025

RAS Cancer Breakthrough? Revolution Medicines CEO Takes Center Stage at Major Biotech Event - StockTitan

Jan 29, 2025

Jan 28, 2025

Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha

Jan 28, 2025

Jan 27, 2025

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Average Target Price from Analysts - MarketBeat

Jan 27, 2025

Jan 24, 2025

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN

Jan 24, 2025

Jan 23, 2025

Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials By Investing.com - Investing.com South Africa

Jan 23, 2025

Jan 23, 2025

Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - Investing.com Canada

Jan 23, 2025

Jan 22, 2025

Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock - MSN

Jan 22, 2025

Jan 22, 2025

Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock By Investing.com - Investing.com Australia

Jan 22, 2025

Jan 19, 2025

Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Jan 19, 2025

Jan 18, 2025

Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey

Jan 18, 2025

Jan 17, 2025

Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com

Jan 17, 2025

Jan 17, 2025

Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Jan 17, 2025

Jan 17, 2025

Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat

Jan 17, 2025

Jan 17, 2025

(RVMD) Trading Advice - Stock Traders Daily

Jan 17, 2025

Jan 17, 2025

Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential - Insider Monkey

Jan 17, 2025

Jan 17, 2025

Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria

Jan 17, 2025

Jan 14, 2025

Stocks Generating Improved Relative Strength: Revolution Medicines - MSN

Jan 14, 2025

Jan 10, 2025

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, UBS Group Analyst Says - Defense World

Jan 10, 2025

Jan 08, 2025

UBS Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat

Jan 08, 2025

Jan 07, 2025

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 07, 2025

Jan 06, 2025

Principal Financial Group Inc. Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World

Jan 06, 2025

Jan 05, 2025

Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $65.82 - Defense World

Jan 05, 2025

Jan 02, 2025

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Jan 02, 2025

Dec 30, 2024

Revolution Medicines (RVMD) Shares Cross Below 200 DMA - Nasdaq

Dec 30, 2024

Dec 30, 2024

Revolution Medicines Becomes Oversold (RVMD) - Nasdaq

Dec 30, 2024

Dec 27, 2024

(RVMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Dec 27, 2024

Dec 27, 2024

Revolution Medicines divulges new GTPase KRAS, NRAS and HRAS inhibitors - BioWorld Online

Dec 27, 2024

Dec 20, 2024

Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com India

Dec 20, 2024

Dec 20, 2024

Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia

Dec 20, 2024

Dec 19, 2024

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News

Dec 19, 2024

Dec 19, 2024

Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com Australia

Dec 19, 2024